Lantern Pharma (NASDAQ: LTRN), an AI-driven precision oncology company, announced updated Phase 2 HARMONIC trial data demonstrating that LP-300, in combination with carboplatin and pemetrexed, provided a progression-free survival (PFS) benefit that increased with treatment duration in patients with EGFR Exon 21 L858R-mutant non-small cell lung cancer (NSCLC) who had progressed following tyrosine kinase inhibitor (TKI) therapy.
The emerging data showed a median PFS of 8.9 months among L858R patients treated through up to six cycles, compared with 8.4 months across the overall L858R cohort. The company noted that LP-300 maintained an exceptionally clean safety and tolerability profile. These results supported a recently FDA-cleared protocol amendment extending LP-300 dosing from six to eight cycles.
This development is significant because EGFR-mutant NSCLC is a common subtype in never-smokers, and patients who progress on TKI therapy have limited options. The HARMONIC trial is evaluating LP-300 specifically in never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. By demonstrating an increasing PFS benefit with continued dosing, LP-300 may offer a new treatment paradigm for this patient population. The extension to eight cycles could allow patients to derive even greater benefit.
The implications for the lung cancer community are substantial: if confirmed in larger studies, LP-300 could become a standard-of-care option for EGFR L858R-mutant patients who have exhausted TKI therapy. For Lantern Pharma, positive HARMONIC data could accelerate the path to registration and commercialization. The company's use of its proprietary RADR platform, which leverages artificial intelligence and machine learning, highlights the growing role of AI in identifying optimal patient populations and drug combinations.
Lantern Pharma's pipeline also includes LP-184 and LP-284, targeting various solid tumors and hematologic malignancies. Additionally, through its subsidiary Starlight Therapeutics, LP-184 is being developed for pediatric CNS cancers. The company recently launched withZeta.ai, a multi-agentic AI co-scientist platform available as a subscription-based research tool, representing a new revenue stream.
The full press release is available at https://ibn.fm/uaAUc. For more information about Lantern Pharma, visit their newsroom at https://ibn.fm/LTRN.
